Page content This document is from our Archive and no action should be taken in reliance on it without specific legal advice. You can perform a search for more recent content. Inside Life Sciences Issue 5: July 2018 Post A high for cannabidiol There has been a huge amount of press interest very recently in medical cannabis, its effects, and whether it should be legalised. Post Pfizer and Flynn win appeal against abuse of dominance decision The Competition Appeal Tribunal (CAT) has upheld appeals by Pfizer Limited and Flynn Pharma Limited in relation to significant fines imposed by the Competition and Markets Authority (CMA) for charging allegedly unfair prices for genericised phenytoin sodium capsules in breach of Chapter II of the Competition Act. Post Advocate General issues SPC Opinion in Teva v Gilead On 25 April, Advocate General Wathelet issued his opinion on the interpretation of Article 3(a) SPC Regulation in the referral from the UK Patents Court in Teva & ors v Gilead following a hearing before the Grand Chamber of the Court of Justice of the EU in February 2018. Post SPC Reform: Commission proposes export manufacturing waiver Following a consultation, the EU Commission has published a proposal for a 'targeted amendment' to the rules relating to supplementary protection certificates (SPCs) in the form of a 'manufacturing export waiver' Post Under the microscope: the gender pay gap in the life sciences sector With the first annual reporting window having closed on 4 April 2018, we look at how the life sciences sector has fared in the first year of mandatory gender pay gap reporting. Post CJEU rules on parallel imports of medical devices Whilst the law relating to the repackaging of imported pharmaceutical products is now largely settled following a series of decisions, a recent case provides further clarification. Post Injunctions: an increasingly flexible and pragmatic approach In recent years, the UK courts have demonstrated that they are prepared to be flexible and pragmatic when considering remedies for patent infringement. Previous Issues Prev Next Issue 13 Apr 2021 Issue 12 Nov 2020 Issue 11 Aug 2020 Issue 10 Jun 2020 Issue 9 Dec 2019 Issue 8 Jul 2019 Issue 7 Mar 2019 Issue 6 Nov 2018 Issue 5 Jul 2018 Issue 4 Mar 2018 Issue 3 Nov 2017 Share
Post A high for cannabidiol There has been a huge amount of press interest very recently in medical cannabis, its effects, and whether it should be legalised.
Post Pfizer and Flynn win appeal against abuse of dominance decision The Competition Appeal Tribunal (CAT) has upheld appeals by Pfizer Limited and Flynn Pharma Limited in relation to significant fines imposed by the Competition and Markets Authority (CMA) for charging allegedly unfair prices for genericised phenytoin sodium capsules in breach of Chapter II of the Competition Act.
Post Advocate General issues SPC Opinion in Teva v Gilead On 25 April, Advocate General Wathelet issued his opinion on the interpretation of Article 3(a) SPC Regulation in the referral from the UK Patents Court in Teva & ors v Gilead following a hearing before the Grand Chamber of the Court of Justice of the EU in February 2018.
Post SPC Reform: Commission proposes export manufacturing waiver Following a consultation, the EU Commission has published a proposal for a 'targeted amendment' to the rules relating to supplementary protection certificates (SPCs) in the form of a 'manufacturing export waiver'
Post Under the microscope: the gender pay gap in the life sciences sector With the first annual reporting window having closed on 4 April 2018, we look at how the life sciences sector has fared in the first year of mandatory gender pay gap reporting.
Post CJEU rules on parallel imports of medical devices Whilst the law relating to the repackaging of imported pharmaceutical products is now largely settled following a series of decisions, a recent case provides further clarification.
Post Injunctions: an increasingly flexible and pragmatic approach In recent years, the UK courts have demonstrated that they are prepared to be flexible and pragmatic when considering remedies for patent infringement.